To read the full story, subscribe or sign in.

Abraxis completes enrollment in phase III clinical study of Abraxane in NSCLC

July 14, 2009

No Comments

BioWorld Science Cancer

Today's news in brief

BioWorld

BioWorld briefs for Nov. 28, 2023.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for November, 28 2023.

Aurinia Therapeutics’ AUR-300 proven useful in systemic sclerosis

BioWorld Science

Aurinia Pharmaceuticals Inc. has investigated their CD206 ligand AUR-300 as a novel therapeutic agent for systemic sclerosis treatment.

Alkermes spinout Mural Oncology launches with lead IL-2 drug

BioWorld

A year after Alkermes plc announced it would divide its oncology and neuroscience efforts into two separate businesses, the Dublin-based company spun out Mural...

Historic MHRA exa-cel win bagged, Crispr/Vertex await FDA nod

BioWorld

With a landmark U.K. approval in hand for Casgevy (exagamglogene autotemcel [exa-cel]) to treat sickle cell disease and transfusion-dependent beta thalassemia,...

Upgrade your daily dose of biopharma and medtech news

Abraxis completes enrollment in phase III clinical study of Abraxane in NSCLC